Compound Evidence File
#EC-2026-0755
SS-31
Filed under Peptides. The bureau holds 143 laboratory returns for this compound from 48 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
48 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 5 | 10.0 | 9.9 | 10.0 | 25 May 2026 | 25 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 27 Apr 2026 | 15 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 10.0 | 9.9 | 10.0 | 10 Feb 2026 | 2 May 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Feb 2026 | 20 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 9 Dec 2025 | 5 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 9.9 | 10.0 | 10 Nov 2025 | 8 Apr 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 10.0 | 9.9 | 10.0 | 9 Jan 2026 | 4 May 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 10.0 | 10.0 | 10.0 | 5 Jan 2026 | 24 May 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 10.0 | 10.0 | 10.0 | 3 Jun 2026 | 1 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 10.0 | 10.0 | 10.0 | 1 Feb 2026 | 14 Mar 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 10.0 | 10.0 | 10.0 | 9 Apr 2026 | 13 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 10.0 | 10.0 | 10.0 | 15 Dec 2025 | 10 May 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 10.0 | 10.0 | 10.0 | 2 May 2026 | 5 Jul 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 9.9 | 9.9 | 10.0 | 20 Feb 2026 | 27 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 23 Jan 2026 | 8 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 10.0 | 1 Jan 2026 | 1 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Jul 2026 | 14 Aug 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 9.9 | 9.9 | 10.0 | 7 Mar 2026 | 8 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 24 Jan 2026 | 26 Apr 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 9.9 | 9.9 | 10.0 | 12 Feb 2026 | 2 Jun 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 9.9 | 9.9 | 10.0 | 4 Mar 2026 | 12 Apr 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 10.0 | 17 Apr 2026 | 5 Jul 2026 |
| Aavant ResearchCASE #VI-2026-0831 | X | 1 | 9.3 | 9.3 | 9.3 | 21 May 2025 | 21 May 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 8.8 | 6.6 | 10.0 | 21 May 2026 | 21 May 2026 |
| Shanghai JinBei Chemical TechnologyCASE #VI-2026-0107 | X | 1 | 8.8 | 8.8 | 8.8 | 2 Apr 2025 | 2 Apr 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 6 | 8.7 | 6.8 | 9.6 | 23 May 2026 | 23 May 2026 |
| Huaian Hanyou PeptideCASE #VI-2026-0297 | X | 1 | 8.6 | 8.6 | 8.6 | 20 Jun 2025 | 20 Jun 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 8 | 8.3 | 6.9 | 9.2 | 24 May 2026 | 24 May 2026 |
| Yiwu Aozuo Trading CoCASE #VI-2026-0798 | X | 5 | 8.3 | 7.9 | 9.3 | 9 Jun 2025 | 19 Jan 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 6 | 7.8 | 6.2 | 8.8 | 25 May 2026 | 25 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 5 | 7.6 | 6.6 | 8.3 | 21 May 2026 | 21 May 2026 |
| The Naughty NeedleCASE #VI-2026-0432 | X | 1 | 7.4 | 7.4 | 7.4 | 9 Jun 2025 | 9 Jun 2025 |
| Shanxi Qianyecao Biotech QYCCASE #VI-2026-0189 | X | 2 | 7.3 | 5.7 | 8.9 | 3 Jul 2025 | 23 May 2026 |
| Xingtai Pukelai Technology CoCASE #VI-2026-0850 | X | 1 | 7.0 | 7.0 | 7.0 | 27 Feb 2025 | 27 Feb 2025 |
| Huayi BiotechnologyCASE #VI-2026-0243 | X | 1 | 6.6 | 6.6 | 6.6 | 9 Jun 2025 | 9 Jun 2025 |
| Bulk Peptide SupplyCASE #VI-2026-0446 | X | 1 | 6.4 | 6.4 | 6.4 | 13 Jun 2025 | 13 Jun 2025 |
| HkRoidsCASE #VI-2026-0784 | X | 1 | 6.4 | 6.4 | 6.4 | 17 Dec 2024 | 17 Dec 2024 |
| YimeiCASE #VI-2026-0081 | X | 4 | 6.2 | 5.3 | 6.8 | 24 Apr 2025 | 24 May 2026 |
| LSPLCASE #VI-2026-0523 | X | 4 | 6.0 | 3.8 | 7.7 | 25 Apr 2025 | 20 May 2026 |
| NextechLabsCASE #VI-2026-0285 | X | 2 | 6.0 | 5.3 | 6.8 | 27 Feb 2025 | 21 May 2026 |
| OupeptideCASE #VI-2026-0435 | X | 9 | 5.8 | 2.9 | 7.8 | 28 Mar 2025 | 24 May 2026 |
| Qingdao VitaConin International TradingCASE #VI-2026-0504 | X | 1 | 5.8 | 5.8 | 5.8 | 25 Apr 2025 | 25 Apr 2025 |
| Peptide CraftersCASE #VI-2026-0994 | X | 1 | 5.7 | 5.7 | 5.7 | 28 Mar 2025 | 28 Mar 2025 |
| Guangzhou Lengiuanhuang CosmeticsCASE #VI-2026-0228 | X | 1 | 5.4 | 5.4 | 5.4 | 13 Jun 2025 | 13 Jun 2025 |
| NuLife PeptidesCASE #VI-2026-0980 | X | 1 | 2.5 | 2.5 | 2.5 | 2 Jul 2025 | 2 Jul 2025 |
| Wuhan Newtop BiotechCASE #VI-2026-0676 | X | 1 | 0.0 | 0.0 | 0.0 | 27 Feb 2025 | 27 Feb 2025 |
| Advanced Technology and IndustrialCASE #VI-2026-0133 | X | 1 | 0.0 | 0.0 | 0.0 | 24 Apr 2025 | 24 Apr 2025 |
Open any subject to view the batch-level evidence for SS-31 alone.